Archives

Use the basic search or click on advanced for more search options.

Advanced Search Basic Search Advanced Search

Publications

Section

Select publication to see the relevant sections.

Publication Date

    E.g., 2018-10-20
    E.g., 2018-10-20

Archive Search

Pages

61 results
11:10 AM, Oct 19, 2018  |  BC Week In Review | Clinical News  |  Regulatory

After three deals, FDA approval, talazoparib joins PARP party

the indication. The approval comes well ahead of Talzenna's December PDUFA date. FDA concurrently approved BRACAnalysis
with chemotherapy. Lynparza has a WAC of $13,886.46 per month, or $166,637.52 per year. Myriad's BRACAnalysis
10:22 PM, Jan 18, 2018  |  BC Week In Review | Clinical News  |  Regulatory

FDA approves AZ's Lynparza for breast cancer

of discontinuations in the chemotherapy arm. Concurrent with Lynparza's approval, FDA approved Lynparza's companion diagnostic BRACAnalysis
5:29 PM, Oct 19, 2017  |  BC Week In Review | Clinical News  |  Regulatory

AZ's Lynparza gets Priority Review for breast cancer

to treat ovarian cancer. Concurrently, FDA accepted for review an sPMA for Lynparza companion diagnostic BRACAnalysis
4:13 PM, Apr 13, 2017  |  BC Week In Review | Company News  |  Deals

Myriad, BeiGene deal

diagnostic to support development of BeiGene's BGB-290 using Myriad's myChoice Homologous Recombination Deficiency (HRD) and BRACAnalysis
12:00 AM, Oct 31, 2016  |  BC Week In Review | Clinical News  |  Clinical Results

Lynparza olaparib: Phase III data

submission plans with FDA. Patients were screened for germline BRCA mutations in SOLO-2 using the BRACAnalysis
12:00 AM, Oct 17, 2016  |  BC Week In Review | Clinical News  |  Clinical Results

Niraparib: Additional Phase III data

2 diagnostics from Myriad Genetics Inc. (NASDAQ:MYGN, Salt Lake City, Utah) in the trial: the BRACAnalysis
12:00 AM, Apr 20, 2015  |  BC Week In Review | Company News  |  Deals

Myriad Genetics, AstraZeneca deal

AstraZeneca and Myriad expanded a 2013 deal and will use Myriad’s BRACAnalysis CDx test to identify …
to respond to the pharma’s Lynparza olaparib. Under the 2013 deal, the partners were using BRACAnalysis
12:00 AM, Feb 02, 2015  |  BC Week In Review | Clinical News  |  Regulatory

Tumor BRACAnalysis CDx regulatory update

Myriad Genetics received CE Mark approval for Tumor BRACAnalysis CDx to detect breast cancer 1 early …
response to platinum-based chemotherapy. Myriad Genetics Inc. (NASDAQ:MYGN), Salt Lake City, Utah   Product: Tumor BRACAnalysis
12:00 AM, Dec 22, 2014  |  BC Week In Review | Clinical News  |  Regulatory

Lynparza olaparib regulatory update

FDA concurrently approved a PMA from Myriad Genetics Inc. (NASDAQ:MYGN, Salt Lake City, Utah) for BRACAnalysis

Pages